Skip to main content
Log in

Synergistic Antitumor Interaction of Human Monocyte Chemotactant Protein-1 Gene Transfer and Modulator for Tumor-Infiltrating Macrophages

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose. In order to evaluate the possibility of synergistic antitumor gene therapy by the gene delivery of monocyte chemotactant protein-1 (MCP-1/MCAF/IE), the effect of a biological response modulater for macrophages on tumor progression of gene transfected tumor cells was studied.

Methods. Cachexia-inducing adenocarcinoma cells (cell line colon 26, clone 20) were transfected with either a control plasmid or MCP-1 cDNA.

Results. The production of MCP-1 reached 70-80 ng/ml in vitro when transfectant cells were cultured at a cell density of 1 × 105 cells/ml for 3 days. Transfection of MCP-1 cDNA did not affect the growth ratein vitro. Also, MCP-1-transfectants formed tumors after intra-footpad inoculation similar in size to the parental cells. The number of infiltrating macrophages in the primary tumor of the transfectant rapidly increased from the 3rd to 5th day after inoculation as revealed by immunohistochemical staining using an antibody against mouse macrophages. An earlier, greater, but no longer-lasting increase in tumor-infiltrating macrophages was induced in tumors by MCP-1 transfection was compared to that induced by the parent cells. On the 10th day after the inoculation, the tumor-infiltrating macrophages in mice inoculated MCP-1 transfectants were decreased to a level similar to that of the parent cells. Groups of mice were treated intraperitoneally with LPS at different times after the inoculation. Tumor cells producing high levels of MCP-1 were significantly lysed by macrophages treated with LPS, whereas parental or control transfected cells were not.

Conclusions. Combination immunotherapy can provide a rationale for the application of MCP-1 treatment to increase immunological responses to cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

REFERENCES

  1. E. Nakashima, N. Mukaida, Y. Kubota, K. Kuno, K. Yasumoto, F. Ichimura, I. Nakanishi, M. Miyasaka, and K. Matsushima. Human MCAF gene transfer enhances the metastatic capacity of a mouse cachectic adenocarcinoma cell line in vivo. Pharm Res. 12(11):1598–1604 (1995).

    PubMed  Google Scholar 

  2. H. Hock, M. Dorsch, U. Kunzendorf, Z. Qin, T. Diamantstein, and T. Blankenstein. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. Proc Natl Acad Sci USA 90(7):2774–8 (1993).

    PubMed  Google Scholar 

  3. Z. Qin, K. S. Kruger, U. Kunzendorf, H. Hock, T. Diamantstein, and T. Blankenstein. Expression of tumor necrosis factor by different tumor cell lines results either in tumor suppression or augmented metastasis. J. Exp Med. 178(1):355–60 (1993).

    PubMed  Google Scholar 

  4. D. A. Clark, H. W. Hirte, and R. N. Buick. Human ovarian carcinoma: evidence for patient-related differences in susceptibility to cytotoxic effectors that attack different cellular subpopulations within a tumour. Br J Cancer. 58(4):415–8 (1988).

    PubMed  Google Scholar 

  5. D. D. Taub, P. Proost, W. J. Murphy, M. Anver, D. L. Longo, D. J. Van, and J. J. Oppenheim. Monocyte chemotactic protein-1 (MCP-1),-2, and-3 are chemotactic for human T lymphocytes. J Clin Invest. 95(3):1370–6 (1995).

    PubMed  Google Scholar 

  6. B. J. Rollins and M. E. Sunday. Suppression of tumor formation in vivo by expression of the JE gene in malignant cells. Mol Cell Biol. 11(6):3125–31 (1991).

    PubMed  Google Scholar 

  7. B. J. Rollins. JE/MCP-1: an early-response gene encodes a monocyte-specific cytokine. Cancer Cells 3(12):517–24 (1991).

    PubMed  Google Scholar 

  8. R. K. Singh and I. J. Fidler. Synergism between human recombinant monocyte chemotactic and activating factor and lipopolysaccharide for activation of antitumor properties in human blood monocytes. Lymphokine Cytokine Res. 12(5):285–91 (1993).

    PubMed  Google Scholar 

  9. S. Huang, R. K. Singh, K. Xie, M. Gutman, K. K. Berry, C. D. Bucana, I. J. Fidler, and E. M. Bar. Expression of the JE/MCP-1 gene suppresses metastatic potential in murine colon carcinoma cells. Cancer Immunol Immunother. 39(4):231–8 (1994).

    PubMed  Google Scholar 

  10. Y. Tanaka, H. Eda, K. Fujimoto, T. Tanaka, T. Ishikawa, and H. Ishitsuka. Anticachectic activity of 5′-deoxy-5-fluorouridine in a murine tumor cachexia model, colon 26 adenocarcinoma. Cancer Res. 50(15):4528–32 (1990).

    PubMed  Google Scholar 

  11. Y. Furutani, H. Nomura, M. Notake, Y. Oyamada, T. Fukui, M. Yamada, C. G. Larsen, J. J. Oppenheim, and K. Matsushima. Cloning and sequencing of the cDNA for human monocyte chemotactic and activating factor (MCAF). Biochem Biophys Res Commun. 159(1):249–55 (1989).

    PubMed  Google Scholar 

  12. P. Gunning, J. Leavitt, G. Muscat, S. Y. Ng, and L. Kedes. A human beta-actin expression vector system directs high-level accumulation of antisense transcripts. Proc Natl Acad Sci USA. 84(14):4831–5 (1987).

    PubMed  Google Scholar 

  13. C. Chen and H. Okayama. High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol. 7(8):2745–52 (1987).

    PubMed  Google Scholar 

  14. Y. Ko, N. Mukaida, A. Panyutich, N. N. Voitenok, K. Matsushima, T. Kawai, and T. Kasahara. A sensitive enzyme-linked immunosorbent assay for human interleukin-8. J Immunol Methods 149(2):227–35 (1992).

    PubMed  Google Scholar 

  15. Y. Nakano, T. Kasahara, N. Mukaida, Y. C. Ko, M. Nakano, and K. Matsushima. Protection against lethal bacterial infection in mice by monocyte-chemotactic and-activating factor. Infect Immun. 62(2):377–83 (1994).

    PubMed  Google Scholar 

  16. K. Matsushima, C. G. Larsen, G. C. DuBois, and J. J. Oppenheim. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med. 169(4):1485–90 (1989).

    PubMed  Google Scholar 

  17. M. W. Carr, S. J. Roth, E. Luther, S. S. Rose, and T. A. Springer. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci USA 91(9):3652–6 (1994).

    PubMed  Google Scholar 

  18. J. M. Wang, A. Hishinuma, J. J. Oppenheim, and K. Matsushima. Studies of binding and internalization of human recombinant monocyte chemotactic and activating factor (MCAF) by monocytic cells. Cytokine. 5(3):264–75 (1993).

    PubMed  Google Scholar 

  19. R. K. Singh, K. Berry, K. Matsushima, K. Yasumoto, and I. J. Fidler. Synergism between human monocyte chemotactic and activating factor and bacterial products for activation of tumoricidal properties in murine macrophages. J Immunol. 151(5):2786–93 (1993).

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Emi Nakashima.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nakashima, E., Kubota, Y., Matsushita, R. et al. Synergistic Antitumor Interaction of Human Monocyte Chemotactant Protein-1 Gene Transfer and Modulator for Tumor-Infiltrating Macrophages. Pharm Res 15, 685–689 (1998). https://doi.org/10.1023/A:1011906600304

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1011906600304

Navigation